Transforming patient care and reducing healthcare costs
- AstraZeneca launches health-tech business Evinova
- Evinova offers knowledge of clinical trial design and study delivery
- Business aims to reduce time and cost of developing new medicines
- Collaborations with Parexel and Fortrea to offer digital health solutions
- Evinova’s expertise can improve patient care and drive healthcare transformation
Public Companies: AstraZeneca (AZN)
Private Companies: undefined, undefined
Key People: Pascal Soriot (Chief Executive)
Factuality Level: 8
Justification: The article provides factual information about AstraZeneca launching Evinova, a health-tech business, and its aim to reduce the time and cost of developing new medicines. It also mentions the company’s collaborations with Parexel and Fortrea. However, the article lacks specific details about the digital health solutions offered by Evinova and does not provide any evidence or data to support the claims made by Chief Executive Pascal Soriot.
Noise Level: 7
Justification: The article provides some information about AstraZeneca launching a health-tech business called Evinova, but it lacks in-depth analysis or evidence to support the claims made. It mainly focuses on the potential benefits of the business without addressing any potential drawbacks or challenges. The article also lacks scientific rigor and does not provide actionable insights or solutions.
Financial Relevance: Yes
Financial Markets Impacted: The launch of AstraZeneca’s health-tech business, Evinova, may have an impact on the company’s financial performance and potentially attract investor interest in the pharmaceutical sector.
Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article discusses the launch of AstraZeneca’s health-tech business, Evinova, which could have financial implications for the company. However, there is no mention of any extreme events or their impact.
www.marketwatch.com 
